We weren’t able to make it to CES this year, but we were keeping a close eye on the new digital health announcements to see if anything really impressed us. Amongst many new wearables and sensors that seemed to bring marginal improvement, there were a few hardware / software announcements that we are looking forward to testing and bringing to our customers.
Validic offers a mobile health API connection that enables healthcare companies to access data from mHealth apps and devices. Their new VitalSnap technology liberates data that was previously trapped in non-connect devices (no Bluetooth/cellular connectivity). Using Validic’s smartphone app, users can share the data from their non-connected devices (blood glucose, scale, etc.) by scanning the device’s screen with their phone’s camera technology (although no picture is actually taken). The app leveraging optical character recognition (OCR) to capture the data and the stores it before it is passed on to Validic’s customers. VitalSnap makes the number of devices supported by Validic increase dramatically and enables patients to continue to use devices that they may feel comfortable with versus transitioning to the new, connected version.
True Wearables is a new sensor company that was founded in 2014. Their first product, Oxxiom, is a tiny, wireless, and disposable pulse oximeter. With a 24+ hour battery life, it provides continuous monitoring of pulse SpO2, pulse rate, and pulse strength and is able to transmit to smartphones and computers via Bluetooth.
We are particularly interested in their device as we are in the process of helping a client think through sensors for an upcoming COPD study. A product like Oxxiom would be ideal as it is small and unobtrusive and wouldn’t interrupt the subjects’ sleep. Although promising, it seems like the Oxxiom still has some work to do as it has yet to achieve FDA approval.
LEVL announced their first product at CES which, like many others, targets the weight loss industry. LEVL is a sensor that uses nanotechnology to measure the concentration of acetone in our breath. Since when our bodies turn fat into energy they are in ketosis, they produce different ketones, including acetone. LEVL promises to provide insight into this metabolic activity which will aid weight loss.
Similar to the Oxxiom, this product seems to have some work to do, but once it is on the market, it could be very valuable in a number of obesity clinical studies. Today, metabolic function is traditionally measured in metabolic chambers which create artificial environments and are very expensive. LEVL’s technology could allow for more ongoing monitoring of ketosis, potentially providing insights into how obesity drugs of the future impact our metabolism.
By Matt Cantor, VP of Business Operations at Koneksa Health